Your shopping cart is currently empty

Motapizone (NAT 05-239) is a selective PDE3 inhibitor that suppresses cytokine release in LPS-induced human alveolar macrophages, increases intracellular cAMP, and inhibits human platelet aggregation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $499 | Inquiry | Inquiry |
| Description | Motapizone (NAT 05-239) is a selective PDE3 inhibitor that suppresses cytokine release in LPS-induced human alveolar macrophages, increases intracellular cAMP, and inhibits human platelet aggregation. |
| In vitro | When administered at a concentration of 10 μM 15 minutes before oxidant treatment, Motapizone showed a 20% reduction in LPS-induced cytokine release from alveolar macrophages under oxidative stress conditions. Importantly, oxidative stress did not significantly affect this inhibitory effect [1]. |
| Synonyms | NAT05-239, NAT 05-239, NAT 05239 |
| Molecular Weight | 260.32 |
| Formula | C12H12N4OS |
| Cas No. | 90697-57-7 |
| Smiles | O=C1NN=C(C=2SC=C(C2)N3C=NC=C3)C(C)C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 1.8 mg/mL (6.91 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.